Author:
Bharti Ram,Mujwar Somdutt,Priyanka ,Gurjeet Singh Thakur,Khatri Neeraj
Funder
Council of Scientific and Industrial Research, India
CSIR - Institute of Microbial Technology
Reference42 articles.
1. In-vitro Cytotoxicity and In-silico Insights of the Multi-target Anticancer Candidates from Haplophyllum tuberculatum;Al-Nour;Borneo J. Pharm.,2021
2. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer;Arora;Oncologist,2021
3. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer;Chan;Cochrane Database Syst. Rev.,2017
4. Dean, J.L., Thangavel, C., McClendon, A.K., Reed, C.A., Knudsen, E.S., 2010. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010 29:28 29, 4018–4032. DOI: 10.1038/onc.2010.154.